TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02427165
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: RPL554 placebo containing no active ingredients
Study: NCT01121289
Drug: NN1218
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 U/kg body weight injected subcutaneously (under the skin)
Study: NCT01771783
Drug: ACEI-ARB-RI
Normalized name: Ri-Mag Plus
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01771783
Drug: ARB-RI-ACEI
Normalized name: Ri-Mag Plus
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01771783
Drug: RI-ACEI-ARB
Normalized name: Ri-Mag Plus
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01510899
Drug: RO4917838
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of RO4917838
Study: NCT00779129
Drug: Pegylated Lyposomal Doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caelyx 35 mg/m2 intravenously, on Day 1, every 3 weeks, during 6 cycles. Patients still achieving clinical benefit after a total of 6 cycles may continue therapy.
Study: NCT00779129
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 600 mg/m2, intravenously, on Day 1, every 6 weeks, during 6 cycles (concomitantly with Caelyx). Patients still achieving clinical benefit after a total of 6 cycles may continue therapy.
Study: NCT02293109
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02293109
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02293109
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02293109
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV or PO
Study: NCT02462161
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will administer placebo two times per day with an intranasal delivery device.
Study: NCT03263091
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets
Study: NCT00135421
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets \& Capsules, Oral, 0 mg, Once daily, Up to 8 weeks followed by 8 weeks of observation.
Study: NCT04101812
Drug: pegylated liposomal doxorubicin (PLD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLD is an anthracycline topoisomerase II inhibitor that is encapsulated in liposomes for intravenous use.
Study: NCT00537719
Drug: GSK716155
Approvals — FDA: no, EMA: no, PMDA: no
Description: albiglutide subcutaneous injection
Study: NCT00537719
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo injection
Study: NCT01896232
Drug: Oral Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally once a day.
Study: NCT01896232
Drug: Intravenous Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously (IV) three times per week.
Study: NCT01662089
Drug: 15 mg Chelate zinc supplement
Normalized name: Zinc, chelated
DrugBank: Zinc (DB01593)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg Chelate zinc additional to standard 5% minoxidil
Study: NCT01662089
Drug: Placebo drug supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drug instead of Zinc supplement
Study: NCT01381094
Drug: AKB-6548
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral dose administered once daily for 42 days
Study: NCT01381094
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral Placebo administered once daily for 42 days
Study: NCT03061708
Drug: AZD2014
Approvals — FDA: no, EMA: no, PMDA: no
Description: mTOR inhibitor
Study: NCT02443402
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One pill daily until discharge
Study: NCT02443402
Drug: Regular Human Insulin
Normalized name: insulin, regular, human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous insulin given to ICU patients with a BG \> 180 mg/DL for two consecutive readings and will be started on Regular Human Insulin adjusted to achieve and maintain a BG target between 110 - 180 mg/dL following standard hospital protocol. Intravenous insulin infusion will be continued until the patient is able to eat and/or transferred to non-ICU service. In previous studies, average length of insulin infusion in patients with stress hyperglycemia was 16.9±19 hours and the amount of IV insulin requirement was 18.6±24.3 U/day.
Study: NCT01737814
Drug: MST-188
Normalized name: MST 600
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00277537
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: BD for 12 weeks
Study: NCT02314806
Drug: Irrigation with gentamicin solution
Normalized name: gentamicin Irrigation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: The surgical bed is irrigated with a gentamicin solution
Study: NCT02314806
Drug: Irrigation with Clindamycin solution
Normalized name: clindamycin Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: The surgical bed is irrigated with a clindamycin solution
Study: NCT03033199
Drug: Probiotic Agent
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: probiotic capsules containing three viable and freezedried strains-Lactobacillus acidophilus,Lactobacillus casei, and Bifidobacterium bifidum：2 capsules, bid x 4 weeks for one cycle. It will be given for one or two cycles.
Study: NCT01707381
Drug: BOL-303259-X
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ophthalmic solution
Study: NCT04721873
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo, titrated as active intervention
Study: NCT00864760
Drug: NEURONTIN® 400 mg capsules, single dose (2 capsules)
Approvals — FDA: no, EMA: no, PMDA: no
Description: B: Active comparator Subjects received Parke-Davis formulated products under fasting conditions
Study: NCT00418288
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous infusion of 1.2pmol/kg/min
Study: NCT04178590
Drug: SRP + placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline application during scaling and root planing
Study: NCT01585129
Drug: Postpartum Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized into this arm will receive one additional dose of gentamicin (1.5 mg/kg) and clindamycin (900mg) in the postpartum setting.
Study: NCT02432807
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01324830
Drug: day 1 to day 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: low to high dose
Study: NCT03360929
Drug: AZD3759
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strength: 50mg/tablet, 100mg/tablet Dosage and administration: Twice daily administration under fasting state.
Study: NCT00251602
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-time 0.25 ml/min infusion over 30 minutes
Study: NCT00003029
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03492164
Drug: [18F]FluorThanatrace ([18F]FTT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-(4-(2-Fluoroethoxy)phenyl)-8,9-dihiydro-2,7,9a-triazabenzo\[cd\]azulen-6(7H)-one also known as \[18F\]FluorThanatrace or \[18F\]FTT is a positron emitting radiopharmaceutical that has been studied in animals for selective measurement of the in vivo inhibition of the PARP-1 nuclear enzyme with positron emission tomography (PET/CT).
Study: NCT01477021
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00391976
Drug: Tobramycin solution for inhalation 300 mg
Normalized name: tobramycin Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobramycin solution for inhalation was supplied in 5 mL liquid-filled low-density polyethylene ampoules containing 300 mg tobramycin. Patients used a nebulizer to inhale the contents of the ampoules.
Study: NCT00889356
Drug: Clindamycin 100mg and Ketoconazole 400mg
Normalized name: clindamycin 100 MG
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 vaginal capsule once a day at night
Study: NCT00889356
Drug: Tetracycline 100mg and Amphotericin B 50mg
Normalized name: amphotericin B / tetracycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: One full applicator, once a day at night
Study: NCT02724033
Drug: Antiemetic
Normalized name: ANTIEMETICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiemetic
Study: NCT03115424
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be recruited and screened prior to undergoing bariatric surgery.Subjects undergoing SG will be randomized 1:1 at months 3 post surgery to Placebo, 0.6mg SQ daily, with weekly titration of 0.6mg until maintenance dose of 3mg/daily reached. Subjects will remain on study drug for duration of study (33 months). After undergoing surgery, study visits will be timed to coincide with the standard clinical follow-up visits at months 3, 6, 9, 12, 18, 24, 30 and 36.
Study: NCT02278601
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution
Study: NCT02582905
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive ingredient matching the active comparators in appearance.
Study: NCT01223664
Drug: Conserved therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral or intravenous administration
Study: NCT00485108
Drug: prednisolone 1%
Normalized name: GENTAMICIN 0.3/PREDNISOLONE 1% OPH SUSP
Approvals — FDA: no, EMA: no, PMDA: no
Description: eye drop once in each eye treated, 4 times / day for 5 days post-laser
Study: NCT00485108
Drug: ketorolac 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: eye drop once in each eye treated, 4 times / day for 5 days post-laser
Study: NCT00677339
Drug: Placebo L-arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo L-arginine once daily
Study: NCT04028388
Drug: ModraDoc006/r
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with twice daily once weekly (BIDW) ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets
Study: NCT02430077
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical to Obeticholic Acid - placebo drug
Study: NCT01548690
Drug: Ornithine Phenylacetate
Normalized name: phenylacetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up to 36 patients will be enrolled into 2 groups \[\~18 with minimal renal dysfunction (Cohort 1) \& \~18 w/ comprised renal function (Cohort 2)\] and receive OCR-002 infusion for at least 72 hrs. OCR-002 will be administered in the vein and pharmacokinetics (pk) assessed for all subjects who receive the infusion.~The first 24 enrolled subjects received OCR-002 at 3 ascending dose levels (DLs 1-3) with a maximum target infusion rate equivalent to 10g/24h.~The remaining 12 patients (\~6 Cohort 1 \& \~6 Cohort 2) will be enrolled and receive identical quantities of OCR-002 at 20g/24hr continuously for 5 days (Dose Level 4).
Study: NCT03698734
Drug: Placebo - Cap
Approvals — FDA: no, EMA: no, PMDA: no
Description: primiparous women with missed abortion between(13 to 24 weeks) will receive 1 capsule of placebo in addition to misopristol
Study: NCT03510793
Drug: balanced anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients undergoing open elective abdominal aortic aneurysm repair will receive balanced (desflurane + remifentanil) anaesthesia
Study: NCT03510793
Drug: Total intravenous anesthesia
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients undergoing open elective abdominal aortic aneurysm repair will receive total intravenous (propofol + remifentanil with target-controlled infusion) anesthesia
Study: NCT01585129
Drug: No postpartum antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized into this arm will not receive any postpartum antibiotics after delivery. They will be managed identically to the other arm in terms of chorioamnionitis (fever pre-delivery). The groups will be managed identically if endometritis (post-partum fever) develops.
Study: NCT01812044
Drug: subtenons control - 0.5 cc of Normal Saline
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00758784
Drug: bromfenac ophthalmic solution 0.06%
Approvals — FDA: no, EMA: no, PMDA: no
Description: bromfenac ophthalmic solution 0.06% bilaterally twice a day
Study: NCT01802359
Drug: No intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is an observational study. Korean male participants receiving mirodenafil as per the prescribing information will be observed.
Study: NCT00645086
Drug: clarithromycin immediate-release tablets
Normalized name: clarithromycin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day course of clarithromycin immediate-release tablets (1 x 500 mg BID)
Study: NCT00474916
Drug: KRN5500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients are seen weekly and dosed for pain with IV medication of active drug/KRN5500 or placebo . The dose can be escalated, from .6 mg/m2, to 1.2, 1.8, and 2.2 mg/m2.
Study: NCT00474916
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline given as dose escalation for placebo
Study: NCT00184587
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03373019
Drug: Chidamide combined with R-GDP
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chidamide: 30mg,PO,biw one week before cycle 1 treatment rituximab 375 mg/m2,ivgtt D0 gemcitabine 1000mg/m2 iv D1,8 dexamethasone 40mg, iv D1-4, cisplatin 25mg/m2 iv D1-4 chidamide :20mg PO Biw, 2 week on , 1 week off
Study: NCT02547623
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone eye drops 1%
Study: NCT00826514
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous placebo, single dose
Study: NCT00116454
Drug: 131 I-lipiodol
Approvals — FDA: no, EMA: no, PMDA: no
Description: intra-arterial hepatic administration of Lipiocis will occur, 11 to 12 weeks after the initial curative treatment
Study: NCT03756090
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral capsule will be administered orally as 125mg capsules, daily on a schedule of 3 weeks (21 days) on, 1 week (7 days) off of a 4 week \[28 days\] cycle.
Study: NCT03756090
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (600mg/m2, D1) cycled every 14 days for the first 4 cycles.
Study: NCT01021943
Drug: spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Half of the subjects will be assigned to receive 25 mg of spironolactone for 6 months
Study: NCT01021943
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half of the subjects will be assigned to receive placebo for 6 months
Study: NCT01859455
Drug: LGT209 50 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active experimental drug
Study: NCT01859455
Drug: LGT209 300 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active experimental drug
Study: NCT01859455
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator
Study: NCT01859455
Drug: Statins (atorvastatin or simvastatin)
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stable doses of atorvastatin or simvastatin
Study: NCT02712775
Drug: Minocycline (yes/no)
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02712775
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline
Study: NCT03040024
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered intravenously after administration of general anesthesia and prior to the first surgical incision.
Study: NCT00635622
Drug: Placebo control substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal application of single-use applicators pre-filled with placebo control substance. The study product will be administered once daily for 5 consecutive days, followed by once weekly application over 2 consecutive additional weeks.
Study: NCT01381536
Drug: GSK1550188 1mg/kg or 10mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV one shot
Study: NCT04046302
Drug: Dinoprostone
Normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) self-inserted by participants 3 hours before scheduled IUD insertion appointment.
Study: NCT04046302
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one tablet of placebo self-inserted by participants 3 hours before scheduled IUD insertion appointment.
Study: NCT00227058
Drug: Orotic acid and Glutathione-(Nutritional Supplements)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00206570
Drug: Estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00264277
Drug: Vitamin K antagonist (Coumarin anticoagulants)
Normalized name: Vitamin K antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02646904
Drug: CERCHIO 10 mg/ml OS
Approvals — FDA: no, EMA: no, PMDA: no
Description: For Children \< 12 years old 10 drops die (5 mg die) for 21 days. For Children \> 12 years old 20 drops die (10 mg die) for 21 days.
Study: NCT01740362
Drug: CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg (2 x 5 mg tablets), single dose
Study: NCT02112110
Drug: [13C]-BMS-791325
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02028949
Drug: Zavedos®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00805207
Drug: testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone gel 1250 ug/d applied transdermally for a total of 21 days. Testing is performed before and at the end of the 21 day intervention.
Study: NCT00805207
Drug: glucocorticoid
Normalized name: Glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 0.013 mg/kg fat-free mass daily taken orally for a total of 21 days. Testing is performed before and at the end of the 21 day intervention.
Study: NCT00002676
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002676
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01403116
Drug: Oral testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Starting dose: 200 mg T (as TU) BID. Doses may be titrated up to a maximum dose of 300 mg T (as TU) BID or down to a minimum dose of 100 mg T (as TU) BID based on serum T values collected at 4-6 hours post AM dose on Days 30 and 60.
Study: NCT01403116
Drug: topical testosterone gel
Normalized name: testosterone Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting dose: 5 g T applied once daily. Doses may be titrated up to a maximum dose of 10 g daily or down to a minimum dose of 2.5 g daily based on serum T values collected at 4-6 hours post AM dose on Days 30 and 60.
Study: NCT02469246
Drug: ABC/3TC
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600/300 mg FDC tablets administered orally once daily
Study: NCT02469246
Drug: ABC/3TC Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally once daily
Study: NCT02469246
Drug: F/TAF Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally once daily
Study: NCT01883505
Drug: Levodopa and carbidopa
Normalized name: carbidopa / levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous continuous administration
Study: NCT01883505
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous continuous administration
Study: NCT01907165
Drug: Disulfiram
Normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00468897
Drug: RSG XR
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSG XR tablets 8 mg enteric-coated tablet formulation consisting of 3mg fast release plus 5mg slow release. Subject will receive one 8mg of RSG XR on each dosing day. The subject will receive a single oral dose of regiment A or B with 240 milliliter (mL) of water.
Study: NCT00216034
Drug: Krestin (PSK)
Approvals — FDA: no, EMA: no, PMDA: no
Description: From 4-8 weeks after surgery to 53-57 weeks after surgery, 3 g/day, PO every day
Study: NCT04626622
Drug: Kagocel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigators could prescribe other drugs in frame of routine clinical practice
Study: NCT04626622
Drug: No one
Normalized name: ALCOHOL 70 g in 100 mL TOPICAL GEL [d.therapino one step hand sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigators don't prescribe any antiviral drugs in frame of routine clinical practice
Study: NCT01941225
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single administration
Study: NCT06367322
Drug: Statin
Normalized name: Statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: The primary objective of this study was to determine whether the use of statin has a protective effect against PEAP.~Patients undergoing ERCP for a specific medical indication were prospectively reviewed and the incidence of PEAP was compared according to whether or not the patients were receiving statin therapy.
Study: NCT00361530
Drug: Statin
Normalized name: Statin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03590860
Drug: LY3322207
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by SC injection
Study: NCT03590860
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by SC injection
Study: NCT01780233
Drug: Fentanyl 400 µg sublingual spray
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01780233
Drug: Actiq® 400 µg transmucosally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Actiq® 400 µg is a solid formulation of fentanyl citrate on a plastic stick that dissolves slowly in the mouth for absorption across the buccal mucosa.
Study: NCT01780233
Drug: Fentanyl citrate injection 100 µg intravenously
Normalized name: fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03530514
Drug: REGN4461
Approvals — FDA: no, EMA: no, PMDA: no
Description: REGN4461